PATENT CLAIM ANALYSIS

Application Number: 15973783
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "715000"]

Abstract:
This invention concerns a method for treatment or prevention of lower urinary tract symptoms with or without pelvic pain in an individual, said method comprising administering to the individual an effective amount of a selective estrogen receptor modulator, or an isomer, isomer mixture or a pharmaceutically acceptable salt thereof.

Claim (Index 10):
The method according to  claim 9  wherein the selective estrogen receptor modulator is selected from a group consisting of:\n (Z)-2-[3-(4-Chloro-1,2-diphenyl-but-1-enyl)phenoxy]ethanol, \n (Z)-2-{2-[4-(4-Chloro-1,2-diphenylbut-1-enyl)phenoxy]ethoxy}ethanol (fispemifene), \n (Z)-{2-[3-(4-Chloro-1,2-diphenylbut-1-enyl)phenoxy]ethyl}dimethylamine, \n (E)-3-{4-Chloro-1-[4-(2-hydroxyethoxy)phenyl]-2-phenyl-but-1-enyl}-phenol, \n (E)-3-{4-Chloro-1-[4-(2-imidazol-1-yl-ethoxy)phenyl]-2-phenyl-but-1-enyl}-phenol, \n (Z)-3-{4-Chloro-1-[4-(2-imidazol-1-yl-ethoxy)phenyl]-2-phenyl-but-1-enyl}-phenol, or raloxifene, \n or any isomer, isomer mixture or pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 4.0
- Percentile: 93.0
- Lexical Diversity: 1.325
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14832649', '13970026', '14597453', '14496281', '15626774']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8053502603656681
- 35 USC 102 Novelty (BERT): 0.5704483870619387
- Combined Prediction Score: 0.7818600730352951
- Mean Citation Score: 445.13821800000005
- Max Citation Score: 598.7485
- Similarity Product: 337.81207406634087

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test